Subsequent Indications in Oncology Drugs: Pathways, Timelines, and the Inflation Reduction Act
Approval histories of new oncology drugs demonstrate the role of post-approval indications in expanding treatment options towards new cancer types, stages, lines, combinations, and mutations. Heterogeneous clinical development pathways provide insights into potential unintended consequences of IRA-related changes surrounding post-approval research and development.
Authors
- Robert J. Nordyke (ORCID: https://orcid.org/0000-0003-2424-7852)
- Jonathan D. Campbell (ORCID: https://orcid.org/0000-0001-6539-1258)
- Julie A. Patterson (ORCID: https://orcid.org/0000-0001-5629-0842)
- James Motyka (ORCID: https://orcid.org/0009-0006-9216-0141)
- John O’Brien
- Rayan Salih
Institutions
- National Health Council (US)
Publication Details
- Journal
- Therapeutic Innovation & Regulatory Science
- Published
- 2024-10-06
- DOI
- https://doi.org/10.1007/s43441-024-00706-6
- Citations
- 5
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 5.65